RGT 691
Alternative Names: RGT-691Latest Information Update: 10 Feb 2024
At a glance
- Originator Regor Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Protein-arginine deiminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation